ATE116640T1 - Substituierte pipecoline-säurederivate als hiv- protease-hemmer. - Google Patents

Substituierte pipecoline-säurederivate als hiv- protease-hemmer.

Info

Publication number
ATE116640T1
ATE116640T1 AT93103712T AT93103712T ATE116640T1 AT E116640 T1 ATE116640 T1 AT E116640T1 AT 93103712 T AT93103712 T AT 93103712T AT 93103712 T AT93103712 T AT 93103712T AT E116640 T1 ATE116640 T1 AT E116640T1
Authority
AT
Austria
Prior art keywords
substituted
acid derivatives
protease inhibitors
hiv protease
pipecoline
Prior art date
Application number
AT93103712T
Other languages
English (en)
Inventor
Paul Cates Anderson
Francois Soucy
Christiane Yoakim
Pierre Lavallee
Pierre Louis Beaulieu
Original Assignee
Bio Mega Boehringer Ingelheim
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Mega Boehringer Ingelheim filed Critical Bio Mega Boehringer Ingelheim
Application granted granted Critical
Publication of ATE116640T1 publication Critical patent/ATE116640T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
AT93103712T 1992-03-13 1993-03-09 Substituierte pipecoline-säurederivate als hiv- protease-hemmer. ATE116640T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US85071692A 1992-03-13 1992-03-13

Publications (1)

Publication Number Publication Date
ATE116640T1 true ATE116640T1 (de) 1995-01-15

Family

ID=25308925

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93103712T ATE116640T1 (de) 1992-03-13 1993-03-09 Substituierte pipecoline-säurederivate als hiv- protease-hemmer.

Country Status (25)

Country Link
US (1) US5807870A (de)
EP (1) EP0560268B1 (de)
JP (1) JP3258422B2 (de)
KR (1) KR950700253A (de)
AP (1) AP393A (de)
AT (1) ATE116640T1 (de)
AU (1) AU670582B2 (de)
CA (1) CA2131185C (de)
CZ (1) CZ285589B6 (de)
DE (1) DE69300043T2 (de)
DK (1) DK0560268T3 (de)
ES (1) ES2066623T3 (de)
FI (1) FI944217A0 (de)
GR (1) GR3015622T3 (de)
HU (2) HUT70617A (de)
IL (1) IL105035A (de)
NO (1) NO302570B1 (de)
NZ (1) NZ251267A (de)
OA (1) OA10092A (de)
PH (1) PH30734A (de)
PL (1) PL176362B1 (de)
RU (1) RU2140911C1 (de)
SK (1) SK280161B6 (de)
WO (1) WO1993018003A1 (de)
ZA (1) ZA931776B (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6071895A (en) 1992-03-11 2000-06-06 Narhex Limited Polar-substituted hydrocarbons
US5888992A (en) 1992-03-11 1999-03-30 Narhex Limited Polar substituted hydrocarbons
DE69333270T2 (de) 1992-03-11 2004-08-05 Narhex Ltd. Aminderivate von oxo- und hydroxy- substituierten kohlenwasserstoffen
JPH07504654A (ja) 1992-03-11 1995-05-25 ナルヘックス　リミテッド オキソ及びヒドロキシ置換炭化水素のアミン誘導体
US5559256A (en) * 1992-07-20 1996-09-24 E. R. Squibb & Sons, Inc. Aminediol protease inhibitors
JP3657002B2 (ja) 1992-08-25 2005-06-08 ジー．ディー．サール アンド カンパニー レトロウイルスプロテアーゼ阻害剤として有用なα−およびβ−アミノ酸ヒドロキシエチルアミノスルホンアミド
US5484926A (en) 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US5846993A (en) * 1992-12-22 1998-12-08 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
EP0610745A3 (en) * 1993-02-09 1994-09-28 Miles Inc Novel aminomethylene derivatives as immunosuppressants.
IL110898A0 (en) * 1993-09-10 1994-11-28 Narhex Australia Pty Ltd Polar-substituted hydrocarbons
US5527829A (en) * 1994-05-23 1996-06-18 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
CA2137406C (en) * 1994-12-06 2005-09-13 Pierre Louis Beaulieu Process for key intermediates for hiv protease inhibitors
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
US5883252A (en) * 1996-01-26 1999-03-16 Vertex Pharmaceuticals Incorporated Aspartyl protease inhibitors
US5962725A (en) 1996-09-05 1999-10-05 Agouron Pharmaceuticals, Inc. Intermediate compounds useful for making HIV protease inhibitors such as nelfinavir
US5705647A (en) * 1996-09-05 1998-01-06 Agouron Pharmaceuticals, Inc. Intermediates for making HIV-protease inhibitors
US5925759A (en) 1996-09-05 1999-07-20 Agouron Pharmaceuticals, Inc. Methods of making HIV-protease inhibitors and intermediates for making HIV-protease inhibitors
US6232333B1 (en) 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
US6001851A (en) * 1997-03-13 1999-12-14 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US6084107A (en) * 1997-09-05 2000-07-04 Agouron Pharmaceuticals, Inc. Intermediates for making HIV-protease inhibitors
US6251906B1 (en) 1998-05-15 2001-06-26 Abbott Laboratories Retroviral protease inhibiting compounds
EP1248600B1 (de) 2000-01-19 2008-05-14 Abbott Laboratories Verbesserte pharmazeutische zusammensetzungen von hiv-proteasehemmern
JP2003528071A (ja) * 2000-03-23 2003-09-24 エラン ファーマスーティカルズ インコーポレイテッド アルツハイマー病治療用組成物および方法
US6992081B2 (en) 2000-03-23 2006-01-31 Elan Pharmaceuticals, Inc. Compounds to treat Alzheimer's disease
US20030096864A1 (en) * 2000-06-30 2003-05-22 Fang Lawrence Y. Compounds to treat alzheimer's disease
US6846813B2 (en) * 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
PE20020276A1 (es) 2000-06-30 2002-04-06 Elan Pharm Inc COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
JP2004502665A (ja) * 2000-06-30 2004-01-29 イーラン　ファーマスーティカルズ、インコーポレイテッド アルツハイマー病を治療する化合物
EP1666452A2 (de) 2000-06-30 2006-06-07 Elan Pharmaceuticals, Inc. Verbindungen zur Behandlung der Alzheimerischen Krankheit
WO2003002122A1 (en) * 2001-06-27 2003-01-09 Elan Pharmaceuticals, Inc. Beta-hydroxyamine derivatives useful in treatment of alzheimer's disease
US20070213407A1 (en) * 2001-06-29 2007-09-13 Elan Pharmaceuticals And Pharmacia & Upjohn Company Llc Compounds to treat Alzheimer's disease
US7662852B2 (en) 2003-05-22 2010-02-16 Lead Chemical Co., Ltd. Compounds and preparations having antiviral effect
JP2008502728A (ja) * 2004-06-10 2008-01-31 ボード、オブ、トラスティーズ、オブ、ミシガン、ステイト、ユニバーシティ リジンからのカプロラクタムの合成
US8106090B2 (en) * 2005-07-20 2012-01-31 Eli Lilly And Company 1-amino linked compounds
WO2008103366A2 (en) * 2007-02-20 2008-08-28 Board Of Trustees Of Michigan State University Catalytic deamination for carprolactam production
US8598364B2 (en) 2007-03-12 2013-12-03 Nektar Therapeutics Oligomer-protease inhibitor conjugates
EP2262538B1 (de) 2008-03-12 2014-12-10 Nektar Therapeutics Oligomer-aminosäure konjugate
BRPI0911733A8 (pt) * 2008-07-24 2017-10-03 Amyris Inc Método para produzir uma amida cíclica, método para produzir uma poliamida, método para produzir a-amino-e-caprolactama, método para produzir e-caprolactama, método para produzir policaprolactama, processo para a síntese de a-amino-e-caprolactama, processo para a síntese da e-caprolactama e método para produzir nylon 6
US20120108501A1 (en) 2009-06-12 2012-05-03 Nektar Therapeutics Protease Inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4851387A (en) * 1986-10-14 1989-07-25 Banyu Pharmaceutical Co., Ltd. 5-substituted amino-4-hydroxy-pentanoic acid derivatives and their use
CA1340588C (en) * 1988-06-13 1999-06-08 Balraj Krishan Handa Amino acid derivatives
JPH07106992B2 (ja) * 1988-06-13 1995-11-15 三菱石油株式会社 ２，６―ジメチルナフタレンの分離方法
EP0361341A3 (de) * 1988-09-28 1991-07-03 Miles Inc. Therapeutika für AIDS auf der Basis von HIV-Protease-Inhibitoren
GB8927915D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Novel alcohols
GB8927913D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
IL100899A (en) * 1991-02-08 1997-06-10 Sankyo Co Beta-amino-alpha- hydroxycarboxylic acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
MY110227A (en) * 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
ZA931777B (en) * 1992-03-13 1993-09-23 Bio Mega Boehringer Ingelheim Substituted pyrrolidine derivatives as HIV protease inhibitors.
IL110255A (en) * 1993-07-16 1998-12-06 Merck & Co Inc Formation and resolution of 2-tert-butylcarboxamido-piperazine
US5480887A (en) * 1994-02-02 1996-01-02 Eli Lilly And Company Protease inhibitors
GB2292146A (en) * 1994-08-11 1996-02-14 Merck & Co Inc HIV protease inhibitors useful for the treatment of AIDS

Also Published As

Publication number Publication date
JPH0673004A (ja) 1994-03-15
NO943383D0 (no) 1994-09-12
FI944217L (fi) 1994-09-13
US5807870A (en) 1998-09-15
NO943383L (no) 1994-09-12
HU211854A9 (en) 1995-12-28
CA2131185A1 (en) 1993-09-16
OA10092A (en) 1996-12-18
KR950700253A (ko) 1995-01-16
DK0560268T3 (da) 1995-06-12
FI944217A7 (fi) 1994-09-13
AP393A (en) 1995-08-07
JP3258422B2 (ja) 2002-02-18
DE69300043T2 (de) 1995-05-24
GR3015622T3 (en) 1995-06-30
ZA931776B (en) 1993-09-24
HUT70617A (en) 1995-10-30
AU670582B2 (en) 1996-07-25
AU3880893A (en) 1993-10-05
RU2140911C1 (ru) 1999-11-10
SK109094A3 (en) 1995-05-10
IL105035A0 (en) 1993-07-08
CA2131185C (en) 1997-05-27
NO302570B1 (no) 1998-03-23
PH30734A (en) 1997-10-17
AP9300495A0 (en) 1993-04-30
IL105035A (en) 1997-07-13
WO1993018003A1 (en) 1993-09-16
EP0560268B1 (de) 1995-01-04
ES2066623T3 (es) 1995-03-01
HU9402613D0 (en) 1994-11-28
FI944217A0 (fi) 1994-09-13
NZ251267A (en) 1996-09-25
DE69300043D1 (de) 1995-02-16
SK280161B6 (sk) 1999-09-10
RU94040841A (ru) 1996-07-20
EP0560268A1 (de) 1993-09-15
CZ223294A3 (en) 1995-11-15
PL176362B1 (pl) 1999-05-31
CZ285589B6 (cs) 1999-09-15

Similar Documents

Publication Publication Date Title
DE69300043D1 (de) Substituierte Pipecoline-Säurederivate als HIV-Protease-Hemmer.
DK0722439T3 (da) HIV-proteaseinhibitorer
FI950650L (fi) Retrovirusproteaasi-inhibiittoreina käyttökelpoisia hydroksietyyliaminosulfoniamideja
FI950651L (fi) Retrovirusproteaasi-inhibiittoreina käyttökelpoisia sulfonyylialkanoyyliaminohydroksietyyliaminosulfoniamideja
FI944804A7 (fi) Pyrimidinyyliasetamideja elastaasin estäjinä
ATE118767T1 (de) 3-substituierte-2-oxindolderivate als entzündungshemmender.
FI933277A7 (fi) Amiinidioli proteaasi-inhibiittorit
MX9102311A (es) Inhibidores de proteasa de vih.
FI933424A7 (fi) Peptidyyli-4-amino-2,2-difluori-3-okso-1,6-heksaanidinihappojohdannaiset tulehdusta vastustavina aineina
FI940659A7 (fi) Heterosyklisesti substituoituja fenyylisykloheksaanikarboksyylihappojohdannaisia
FI962488L (fi) HIV:n proteaasin inhibiittoreita
FI942976A7 (fi) 5-amino-8-metyyli-7-pyrrolidinyylikinoliini-3-karboksyylihappojohdannaiset
DK0937036T3 (da) Substituerede 4-biphenyl-4-hydroxysmørsyrederivater som matrixmetalprotease-inhibitorer
FI941712L (fi) Heterosykliset iminobismetyleenibisfosfonihappojohdannaiset
DE59402621D1 (de) Fluor-trifluormethylbenzoesäure-Derivate
FI941064A7 (fi) Asyylioksiheksaanihappojohdannaiset
TR27776A (tr) 2-oksimino-2-tiyenil-asetik asit türevleri.
DE59408911D1 (de) Phosphorsäure-Derivate als Schädlingsbekämpfungsmittel
NL193104B (nl) Rechthoekig pallet.
DE69418656D1 (de) 2-acyloxycephemderivate als elastaseinhibitoren
NO950212L (no) Indolinyl-N-hydroksyurinstoff- og -N-hydroksamsyrederivater som lipoksygenase-inhibitorer
DE69325094D1 (de) N-T-BUTYL-ANDROST-3, 5-DIEN-17-beta-CARBOXAMID-3-CARBONSÄURE POLYMORPHA
FR2711088B1 (fr) Démonte-palettes.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner